CUPERTINO, Calif., Aug. 4, 2011 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2011. Total revenues increased to $7.8 million for the three months ended June 30, 2011 from $7.3 million for the three months ended June 30, 2010. Net loss for the three […]
CUPERTINO, Calif., July 28, 2011 /PRNewswire via COMTEX/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) second quarter 2011 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, August 4, 2011 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo:
DURECT Corporation Invites You to Join its Second Quarter 2011 Earnings Conference Call Read More »
Zogenix to Develop and Commercialize Proprietary Long-Acting Risperidone Formulation for Needle-Free Subcutaneous Administration Using the DosePro(R) Delivery System and DURECT’s SABER(TM) Depot Technology Potential to Address $16 Billion World-Wide Antipsychotics Market SAN DIEGO and CUPERTINO, Calif., July 12, 2011 (GLOBE NEWSWIRE) — Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment
CUPERTINO, Calif., June 24, 2011 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) today reported that Pfizer Inc. (NYSE: PFE) has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for REMOXY®, a controlled-release form of oxycodone designed to discourage common methods of tampering. Pfizer
Pfizer Receives Complete Response Letter from FDA for REMOXY® Read More »
CUPERTINO, Calif., June 3, 2011 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that Jim Brown, President and CEO, will be presenting at the Jefferies Healthcare Conference on Tuesday, June 7 at 4:30 p.m. Eastern time. The conference is being held at the Grand Hyatt in New York. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A live audio
DURECT to Present at the Jefferies Healthcare Conference Read More »
CUPERTINO, Calif., June 2, 2011 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Joseph Stauffer, Chief Medical Officer and Executive Vice President, Corporate Strategy has resigned effective June 21, 2011 to pursue other opportunities. Dr. Stauffer and DURECT have entered into a consulting agreement through December 31, 2011. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) “We
DURECT Announces Resignation of Chief Medical Officer Read More »
CUPERTINO, Calif., May 12, 2011 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at the UBS Global Specialty Pharmaceuticals Conference on Tuesday, May 24 at 10:00 a.m. London Time. The conference is being held at the UBS offices in London, England (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A
DURECT to Present at the UBS Global Specialty Pharmaceuticals Conference Read More »
CUPERTINO, Calif., May 5, 2011 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2011. Total revenues increased to $8.6 million for the three months ended March 31, 2011 from $7.7 million for the three months ended March 31, 2010. Net loss for the three
DURECT Corporation Announces First Quarter 2011 Financial Results and Update of Programs Read More »
CUPERTINO, Calif., April 28, 2011 /PRNewswire via COMTEX/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) first quarter 2011 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 5, 2011 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo:
DURECT Corporation Invites You to Join its First Quarter 2011 Earnings Conference Call Read More »
CUPERTINO, Calif., April 11, 2011 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today top-line results from a Phase II clinical trial in chronic low back pain for ELADUR(R) (TRANSDUR(R)-Bupivacaine), DURECT’s proprietary investigational transdermal bupivacaine pain patch. This study was conducted by DURECT’s collaborator, King Pharmaceuticals, which is now owned by Pfizer (NYSE: PFE).
